Literature DB >> 20371510

Relationships between age and late progression of Parkinson's disease: a clinico-pathological study.

Peter A Kempster1, Sean S O'Sullivan, Janice L Holton, Tamas Revesz, Andrew J Lees.   

Abstract

To investigate the relationships between age, the advanced clinical stages of Parkinson's disease and neuropathology, we surveyed 129 case records from donors with pathologically proven Parkinson's disease at the Queen Square Brain Bank for Neurological Disorders. Cases were separated into five groups according to age at death, thus comparing patients who reached the advanced stage of the disease at different ages. Four milestones of advanced disease (frequent falls, visual hallucinations, dementia and need for residential care) occurred at a similar time from death in each group. There were no significant differences in disease duration across these age groupings, nor were there differences in the severity and distribution of Lewy body and other pathologies. The milestones of dementia (P < 0.0005) and visual hallucinations (P = 0.02) as well as the accumulation of multiple milestones (P < 0.0005) were associated with high cortical Lewy body scores. Demented cases also had significantly more Alzheimer neurofibrillary and amyloid-beta plaque pathology. Correlation analysis showed that the time intervals between disease onset and recording of milestones were strongly influenced by age at onset (P < 0.0001) and by total disease duration (P < 0.0001). The advanced disease phase plays out in a similar fashion at whatever age it occurs, with a common pathological endpoint. The clinico-pathological comparisons for the final stage of Parkinson's disease do support a staging system based on the rostral extent and severity of Lewy body pathology, although other pathologies may play a synergistic role in causing cognitive disability. The chief effects of age on the rate of progression are seen over the early-middle part of the disease. An exponential curve for clinical progression provides the best explanation for these observations about age and the disease course.

Entities:  

Mesh:

Year:  2010        PMID: 20371510     DOI: 10.1093/brain/awq059

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  95 in total

Review 1.  Late-stage Parkinson disease.

Authors:  Miguel Coelho; Joaquim J Ferreira
Journal:  Nat Rev Neurol       Date:  2012-07-10       Impact factor: 42.937

Review 2.  Role of the pedunculopontine nucleus in controlling gait and sleep in normal and parkinsonian monkeys.

Authors:  C Karachi; Chantal Francois
Journal:  J Neural Transm (Vienna)       Date:  2017-01-13       Impact factor: 3.575

Review 3.  Safety and Tolerability of Pharmacotherapies for Parkinson's Disease in Geriatric Patients.

Authors:  Martin Klietz; Stephan Greten; Florian Wegner; Günter U Höglinger
Journal:  Drugs Aging       Date:  2019-06       Impact factor: 3.923

4.  PPNa-DBS for gait and balance disorders in Parkinson's disease: a double-blind, randomised study.

Authors:  Marie-Laure Welter; Adele Demain; Claire Ewenczyk; Virginie Czernecki; Brian Lau; Amine El Helou; Hayat Belaid; Jérôme Yelnik; Chantal François; Eric Bardinet; Carine Karachi; David Grabli
Journal:  J Neurol       Date:  2015-04-23       Impact factor: 4.849

5.  Regional changes in the type 1 cannabinoid receptor are associated with cognitive dysfunction in Parkinson's disease.

Authors:  Jenny Ceccarini; Cindy Casteels; Rawaha Ahmad; Melissa Crabbé; Laura Van de Vliet; Heleen Vanhaute; Mathieu Vandenbulcke; Wim Vandenberghe; Koen Van Laere
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-07-24       Impact factor: 9.236

6.  Dementia in long-term Parkinson's disease patients: a multicentre retrospective study.

Authors:  Jennifer Y Y Szeto; Courtney C Walton; Alexandra Rizos; Pablo Martinez-Martin; Glenda M Halliday; Sharon L Naismith; K Ray Chaudhuri; Simon J G Lewis
Journal:  NPJ Parkinsons Dis       Date:  2020-01-07

Review 7.  Cortical afferent inhibition abnormalities reveal cholinergic dysfunction in Parkinson's disease: a reappraisal.

Authors:  Raffaele Nardone; Francesco Brigo; Viviana Versace; Yvonne Höller; Frediano Tezzon; Leopold Saltuari; Eugen Trinka; Luca Sebastianelli
Journal:  J Neural Transm (Vienna)       Date:  2017-08-12       Impact factor: 3.575

8.  Neuropathologic substrates of Parkinson disease dementia.

Authors:  David J Irwin; Matthew T White; Jon B Toledo; Sharon X Xie; John L Robinson; Vivianna Van Deerlin; Virginia M-Y Lee; James B Leverenz; Thomas J Montine; John E Duda; Howard I Hurtig; John Q Trojanowski
Journal:  Ann Neurol       Date:  2012-10-04       Impact factor: 10.422

9.  Prognosis and Neuropathologic Correlation of Clinical Subtypes of Parkinson Disease.

Authors:  Eduardo De Pablo-Fernández; Andrew J Lees; Janice L Holton; Thomas T Warner
Journal:  JAMA Neurol       Date:  2019-04-01       Impact factor: 18.302

10.  Expression of human A53T alpha-synuclein in the rat substantia nigra using a novel AAV1/2 vector produces a rapidly evolving pathology with protein aggregation, dystrophic neurite architecture and nigrostriatal degeneration with potential to model the pathology of Parkinson's disease.

Authors:  James B Koprich; Tom H Johnston; M Gabriela Reyes; Xuan Sun; Jonathan M Brotchie
Journal:  Mol Neurodegener       Date:  2010-10-28       Impact factor: 14.195

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.